Single-agent bevacizumab is an effective treatment in recurrent glioblastoma

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405;
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidozcelik, melike/AAS-7557-2020
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorErdogan, Bulent
dc.contributor.authorTurkmen, Esma
dc.contributor.authorOzcelik, Melike
dc.contributor.authorEsenkaya, Asim
dc.contributor.authorSaygi, Haci Mehmet
dc.date.accessioned2024-06-12T11:02:41Z
dc.date.available2024-06-12T11:02:41Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). We identified patients with histologically confirmed glioblastoma and World Health Organization Grade III glioma who were previously treated with temozolomide plus radiotherapy and received 10 mg/kg bevacizumab intravenous infusion every 2 weeks until disease progression for recurrent disease. A total 24 patients included to this study. Twenty-two patients had GBM, and two patients had WHO grade III glioma. No complete response was observed, five patients (20.8 %) had partial response, nine patients (37.5 %) had stable diseases, and ten patients (41.7 %) had progressive diseases. The overall response rate was 20.8 %. The 6-month PFS rate (PFS6) and median PFS were determined as 37.5 % and 4.1 months, respectively. Median OS was 6.4 months. Performance status of 17 (70.8 %) patients was improved following bevacizumab regimen. Univariate analysis showed that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS (p < 0.001) and OS (p < 0.020). Bevacizumab-related adverse effects were observed in 13 (54.1 %) patients. Grade 3-4 toxicity was observed in 4 (16.6 %) patients. Therapy interruptions were experienced in two patients due to adverse effects. Single-agent bevacizumab is an effective and safe treatment alternative in recurrent GBM. IPS following bevacizumab therapy was a significant predictor of both PFS and OS.en_US
dc.identifier.doi10.1007/s12032-014-0460-3
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue2en_US
dc.identifier.pmid25572814en_US
dc.identifier.scopus2-s2.0-84920774152en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-014-0460-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21379
dc.identifier.volume32en_US
dc.identifier.wosWOS:000347775900016en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGlioblastomaen_US
dc.subjectBevacizumaben_US
dc.subjectSingle Agenten_US
dc.subjectPhase-Ii Trialen_US
dc.subjectAdjuvant Temozolomideen_US
dc.subjectPlus Irinotecanen_US
dc.subjectGliomasen_US
dc.subjectChemotherapyen_US
dc.subjectRadiotherapyen_US
dc.subjectProgressionen_US
dc.subjectConcomitanten_US
dc.subjectExpressionen_US
dc.subjectRadiationen_US
dc.titleSingle-agent bevacizumab is an effective treatment in recurrent glioblastomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu